The State of California, through the California Department of Health Care Access and Information (HCAI), is requesting information concerning potential partnerships in support of the CalRx School Albuterol Access Initiative under the California Affordable Drug Manufacturing Act of 2020. This statewide initiative aims to create a centralized ordering system and provide an emergency stock supply of no fewer than two (2) 90 mcg/actuation albuterol sulfate inhalation aerosol metereddose inhalers (MDIs) and twenty-five (25) single-use disposable holding chambers/spacers to each of California’s 10,000 transitional kindergarten (TK) through grade 12 schools annually at a low price, inclusive of shipping costs. This Request for Information (RFI) seeks to gather relevant information from potential partners to evaluate their products, practices, and capabilities for manufacturing and/or distributing generic albuterol 90 mcg/actuation MDIs and single-use disposable holding chambers/spacers to TK–12 schools, school districts, county offices of education, and/or charter schools in California. Responses will help HCAI assess potential partnerships and develop a procurement process for schools. HCAI is also investigating affordability and accessibility of albuterol MDIs in the broader market and seeks to gather relevant information from potential partners who are interested in manufacturing and/or distributing a generic albuterol 90 mcg/actuation MDI under the CalRx label for all Californians through typical pharmaceutical pathways such as retail and mail-order pharmacies. In this arrangement, the albuterol MDI would be manufactured and/or distributed on behalf of CalRx with CalRx branding.
